These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37653613)

  • 21. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Napsin A is a specific marker for ovarian clear cell adenocarcinoma.
    Yamashita Y; Nagasaka T; Naiki-Ito A; Sato S; Suzuki S; Toyokuni S; Ito M; Takahashi S
    Mod Pathol; 2015 Jan; 28(1):111-7. PubMed ID: 24721826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
    Mackay HJ; Brady MF; Oza AM; Reuss A; Pujade-Lauraine E; Swart AM; Siddiqui N; Colombo N; Bookman MA; Pfisterer J; du Bois A;
    Int J Gynecol Cancer; 2010 Aug; 20(6):945-52. PubMed ID: 20683400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphovascular invasion as a criterion for adjuvant chemotherapy for FIGO stage I-IIa clear cell carcinoma, mucinous, low grade serous and low grade endometrioid ovarian cancer.
    Delvallée J; Cancel M; Body G; Bendifallah S; Touboul C; Dabi Y; Collinet P; Coutant C; Akladios C; Lavoué V; Bolze PA; Huchon C; Bricou A; Canlorbe G; Ballester M; Carcopino X; Mimoun C; Darai E; Ouldamer L
    J Gynecol Obstet Hum Reprod; 2021 Dec; 50(10):102193. PubMed ID: 34224900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
    Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.
    Kuroda T; Hirohashi Y; Torigoe T; Yasuda K; Takahashi A; Asanuma H; Morita R; Mariya T; Asano T; Mizuuchi M; Saito T; Sato N
    PLoS One; 2013; 8(6):e65158. PubMed ID: 23762304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
    Lopacinska-Jørgensen J; Oliveira DVNP; Novotny Wayne; Høgdall CK; Høgdall EV
    PLoS One; 2021; 16(7):e0255142. PubMed ID: 34320033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register.
    Trabert B; Aarestrup J; Ulrich LG; Wentzensen N; Sørensen TIA; Baker JL
    Gynecol Oncol; 2018 Mar; 148(3):547-552. PubMed ID: 29331371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Danish Gynecological Cancer Nursing Database: Creating Evidence for Quality Improvements in Preoperative and Postoperative Cancer Care.
    Seibæk L; Jakobsen DH; Høgdall C
    Int J Gynecol Cancer; 2018 May; 28(4):802-807. PubMed ID: 29470187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
    Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
    Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic intestinal carcinomas simulating primary ovarian clear cell carcinoma and secretory endometrioid carcinoma: a clinicopathologic and immunohistochemical study of five cases.
    Young RH; Hart WR
    Am J Surg Pathol; 1998 Jul; 22(7):805-15. PubMed ID: 9669343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of Japan Society of Obstetrics and Gynecology (JSOG): disparity between serous carcinoma and clear cell carcinoma.
    Yamagami W; Nagase S; Takahashi F; Ino K; Hachisuga T; Mikami M; Enomoto T; Katabuchi H; Aoki D
    J Gynecol Oncol; 2020 Jul; 31(4):e45. PubMed ID: 32026659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Storage policies and use of the Danish Newborn Screening Biobank.
    Nørgaard-Pedersen B; Hougaard DM
    J Inherit Metab Dis; 2007 Aug; 30(4):530-6. PubMed ID: 17632694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
    Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
    J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis.
    Tanaka YO; Okada S; Satoh T; Matsumoto K; Oki A; Saida T; Yoshikawa H; Minami M
    Cancer Imaging; 2016 Feb; 16():3. PubMed ID: 26873307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.
    Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z
    Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A serum based analysis of ovarian epithelial tumorigenesis.
    Nolen B; Marrangoni A; Velikokhatnaya L; Prosser D; Winans M; Gorelik E; Lokshin A
    Gynecol Oncol; 2009 Jan; 112(1):47-54. PubMed ID: 19007974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Borderline ovarian tumors in Denmark 1997-2018: Time trends in incidence by histology, age and educational level.
    Baandrup L; Faber MT; Aalborg GL; Kjaer SK
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):436-443. PubMed ID: 33010027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.